Filing Details
- Accession Number:
- 0001104659-20-004422
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-01-15 20:02:43
- Reporting Period:
- 2020-01-13
- Accepted Time:
- 2020-01-15 20:02:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1621227 | Adaptimmune Therapeutics Plc | ADAP | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1661780 | Katrina Helen Tayton-Martin | C/O Adaptimmune Therapeutics Plc, 60 Jubilee Avenue, Milton Park Abingdon X0 OX14 4RX | Chief Business Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| American Depositary Shares | Disposition | 2020-01-13 | 50,000 | $4.00 | 0 | No | 4 | S | Direct | |
| American Depositary Shares | Disposition | 2020-01-13 | 50,000 | $5.00 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019.
- These ADSs were sold in multiple transactions at a price of $4.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote.
- These ADSs were sold in multiple transactions at a price of $5.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote.
Billionaire Hedge Funds
